The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients

Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients

June 20, 2015 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—A new study has identified myocardial and vascular abnormalities in patients with newly diagnosed, treatment-naive rheumatoid arthritis (RA).

You Might Also Like
  • The Effects of Early RA Treatment on CVD
  • SLE Patients May Not Receive Enough Cardiovascular Disease Assessment & Treatment
  • Patients with Large-Vessel Abnormalities Present Diagnostic Dilemma for Rheumatologists

“The study suggests cardiac abnormalities already exist in newly diagnosed patients with RA,” senior author Dr. Maya Buch of the University of Leeds in the UK told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Specifically, a reduction in the thickness of the left ventricle was seen. Over time, this can be associated with reduced heart function. An increase in arterial stiffness was also recorded, which has been associated with increased cardiovascular events. These are fascinating data, as we did not necessarily expect to see changes so early on,” she said.

Dr. Buch presented the findings on June 12 at the European League Against Rheumatism (EULAR) Annual Congress in Rome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with RA have abnormalities in left ventricular remodeling, but to date cardiac studies have not been conducted in patients with early, treatment-naive disease.

To investigate, Dr. Buch and colleagues performed cardiac magnetic resonance imaging in 66 patients with early RA and no history of cardiovascular disease and 30 healthy controls matched by age, sex, and blood pressure.

The RA patients had significantly reduced aortic distensibility and increased arterial stiffness compared to the control group. Their left ventricular and right ventricular end-systolic and end-diastolic volumes were also significantly lower. There was a trend toward lower left ventricular mass index in the RA patients. Four of the RA patients with focal non-ischemic patterns of late gadolinium enhancement showed signs of overt inflammation and fibrosis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The study is part of a randomized controlled trial comparing standard disease-modifying anti-rheumatic drugs (DMARDs) to anti-tumor necrosis factor (anti-TNF) therapy, Dr. Buch told Reuters Health.

“Longitudinal evaluation with repeat cardiac MRI will allow us to answer whether the abnormalities we have reported improve, whether this depends on reduction in disease activity, and whether it matters how this is achieved, i.e., DMARD versus anti-TNF. We also wish to evaluate other parameters of cardiovascular health, including exercise capacity. This work is part of a wider program of research being conducted in the Leeds ‘CARDIO-AID’ group,” she said.

Epidemiological studies have shown that DMARD treatment reduces the risk of cardiovascular events in RA patients, while anti-TNF treatment is associated with a greater reduction in cardiovascular event risk, Dr. Buch said. Patients with established RA who have reduced disease activity also have lower risk of cardiovascular events, she added.

“In early RA patients such as those investigated in our study, the presence of abnormalities and impact of DMARD has not been evaluated,” she said.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: anti-tumor necrosis factor, Cardiac, disease-modifying antirheumatic drugs, EULAR, Rheumatiod arthritis

You Might Also Like:
  • The Effects of Early RA Treatment on CVD
  • SLE Patients May Not Receive Enough Cardiovascular Disease Assessment & Treatment
  • Patients with Large-Vessel Abnormalities Present Diagnostic Dilemma for Rheumatologists
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)